2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.
Craig Sauter, MD, is director of the Blood and Marrow Transplant Program at Cleveland Clinic. Brian T. Hill, MD, PhD, is director of the Lymphoid Malignancies Program and a staff physician at the Cleveland Clinic Taussig Cancer Institute. In this video, they discuss the benefit of using CAR T-cell therapy following chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL).
Data from the ZUMA-7 (NCT03391466) exploring axicabtagene ciloleucel (Yescarta) and TRANSFORM (NCT03575351) assessing lisocabtagene maraleucel (Breyanzi) suggest that these agents are more effective than standard therapy in the second-line setting. Findings from the BELINDA trial (NCT03570892), however, showed that tisagenlecleucel (Kymriah) was not superior to standard salvage therapy in this trial.
Sauter and Hill note that there are key differences between the 3 studies that affected the results. As such, salvage chemotherpy vs CAR T-cell therapy in this patient population remains an open question.